Rubicon Founders purchased 175,142 shares of Privia Health Group; estimated trade size of $3.95 million based on quarterly average pricing.
Post-trade, Rubicon Founders holds 5,948,664 shares valued at $122.36 million.
Privia Health Group now accounts for 88.92% of the fund's reportable AUM, underscoring its significance in the portfolio.
According to an SEC filing dated May 15, 2026, Rubicon Founders LLC increased its holdings in Privia Health Group (NASDAQ:PRVA) by 175,142 shares during the first quarter. The estimated transaction value was $3.95 million, calculated using the average closing prices for the quarter. The quarter-end value of the position fell by $14.53 million, a figure that reflects both the trading activity and changes in share price.
| Metric | Value |
|---|---|
| Revenue (TTM) | $2.25 billion |
| Net income (TTM) | $21.76 million |
| Market capitalization | $2.94 billion |
| Price (as of market close May 14, 2026) | $23.24 |
Privia Health Group is a national healthcare platform specializing in physician enablement and value-based care solutions. The company leverages technology and coordinated care models to support independent providers and medical groups, driving operational efficiency and improved patient experiences.
With a scalable business model and a focus on aligning financial incentives, Privia Health positions itself as a strategic partner for healthcare organizations navigating the shift to value-based care.
Rubicon Founders increasing its stake in Privia Health Group during the first quarter is a noteworthy event for investors. It demonstrates the hedge fund has a bullish outlook towards the stock, so much so that Privia Health now represents nearly 90% of the firm’s AUM. As a result, the fund’s performance depends almost entirely on this one stock.
A deeper look into Privia Health Group’s financials reveals a strong company. It ended 2025 with $2.1 billion in revenue, up an impressive 22% year over year. Its 2025 net income rose 59% over 2024 to $22.9 million. Its balance sheet was outstanding with $1.4 billion in total assets compared to $578.4 million in total liabilities and no debt.
The company followed 2025 with accelerating sales in the first quarter of 2026. Revenue rose 26% year over year to $603.8 million, and Privia Health expects full-year revenue to reach around $2.4 billion.
This performance suggests customers are finding its solutions are fulfilling an unmet need in the healthcare industry, and bodes well for Privia Health’s ongoing success. Consequently, its stock looks like a worthwhile long-term investment.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.